Why the study?
Despite guideline recommendations for first-line single-pill combinations in hypertension, this approach shifts away from stepped-care strategies, and practicing physicians have expressed concerns about adopting it.
Does first-line treatment with single-pill combinations improve blood pressure control and adherence in patients with hypertension?
Does first-line treatment with single-pill combinations improve blood pressure control and adherence in patients with hypertension?
This review addresses barriers and provides strategies for implementing the guideline-recommended use of single-pill combinations as first-line therapy for hypertension.
Endorses first-line SPCs for rapid BP control; leaves open need for updated outcome trials in contemporary populations.
: The 2008 European Society of Cardiology/European Society of Hypertension guidelines recommend the first-line prescription of two antihypertensive drugs in single-pill combinations (SPCs), also known as fixed-dose combinations, for the treatment of most patients with hypertension. This recommendation is based on a large amount of data, which shows that first-line treatment with SPCs supports reaching blood pressure targets rapidly and reducing cardiovascular outcome risk while keeping the therapeutic strategies as simple as possible and fostering adherence and persistence. As this approach constitutes a big shift from the stepped-care approaches that have been dominant for many years, practicing physicians have expressed concerns about using SPCs as first-line agents. In this review, we will discuss the barriers to the uptake of this recommendation. We will also offer suggestions to reduce the impact of these barriers and address specific concerns that have been raised.
No takes yet. Share an insight, caveat, or question.
Campana et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: